S&P MAINTAINS STRONG BUY OPINION ON SHARES OF NPS PHARMACEUTICALS
(S&P Capital IQ) We keep our 12-month target price at $14. Q4 net loss of $0.14, vs. $0.10 loss, is narrower than our $0.17 loss view on lower costs. We narrow our '13 loss forecast $0.08 to $0.19, and raise '14's estimate by $0.18 to $0.43 EPS. Despite recent volatility, the shares remain significantly undervalued, in our view. Although we see limited visibility into the nascent Gattex launch until the second half of '13, we are encouraged by reports of favorable payor reception of Gattex's premium price. With $100M in cash, we see NPSP as solidly funded to execute on the Gattex launch.
BS...as I have posted before, this is a low priced short and trade stock. If any of the funds thought this company has an upside potential they would be buying until npsp had to issue more shares. this is not some cure for cancer stock or company, it is a dream that a few people will be helped with the short bowel problem.
unfortunately this stock has no great upside in the near future and will be returning to the 4 and 5 level
and possibly 3 like it was...i'm really disappointed npsp has fooled us once again.
sure kasket, thats why Fidelity and Vanguard hold HUGE POSITIONS, and NPS is 90% inst owned. oh i forgot you're piddly #$%$ retail investing brain is smarter than big institutions holding $millions of dollars of shares, man are you bright.